Compare Novartis AG (NVS) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Global X SuperDividend ETF — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Global X SuperDividend ETF trades at $24.54. The key difference: Novartis AG pays a 3.02% dividend while Global X SuperDividend ETF pays none, and Novartis AG is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| NVS | SDIV | |
|---|---|---|
Market Cap | $298.18B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $26.34 |
52-Week Low | $118.55 | $22.90 |
Enterprise Value | $339.50B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
SDIV trades at $24.81, up 1.02% with a neutral technical signal. The ETF maintains a consistent dividend payout of $0.18 monthly, providing a high yield for income-focused investors. Recent news highlights SDIV's role in diversification away from AI-heavy portfolios, with Seeking Alpha upgrading it to a buy rating citing attractive valuation and 9.29% yield. Technical indicators show mixed signals with bearish moving averages but neutral oscillators.
SDIV offers exposure to global high-dividend stocks with minimal tech exposure, appealing during market volatility. Key risks include concentration in financials and energy sectors, interest rate sensitivity, and geopolitical factors affecting dividend sustainability. The fund's 6% yield target provides income stability but requires monitoring of underlying holdings' financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
